- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00986752
Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease (ISAR-STATH)
Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease
Study Overview
Status
Conditions
Detailed Description
The superficial femoral artery is a common place for arteriosclerosis in patients symptomatic for lower extremity vascular disease. Advances in percutaneous transluminal angioplasty (PTA) and stenting have provided new options for the treatment of the disease in this arterial segment. Despite the initial technical success rate of more than 95% the late clinical failure remains an important concern.
Restenosis after PTA occurs in 40-60% within one year. Percutaneous removal of the obstructive material through atherectomy may reduce restenosis rate. So far, data in support of excisional atherectomy derive from registries. Another attempt to reduce restenosis is the use of paclitaxel eluting balloons (PEB). First clinical studies suggest that the use of PEBs during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization.
There is no randomized comparison of this three different interventional strategies. Thus the aim of this study is to evaluate the efficacy of these strategies in terms or reduction of diameter stenosis at follow-up angiogram.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Klaus Tiroch, MD
- Phone Number: 1538 +49-89-1218
- Email: tiroch@dhm.mhn.de
Study Contact Backup
- Name: Tarek Ibrahim, MD
- Phone Number: 4018 +49 89-1218
- Email: ibrahim@dhm.mhn.de
Study Locations
-
-
-
Muenchen, Germany, 80636
- Recruiting
- Deutsches Herzzentrum
-
Contact:
- Massimiliano Fusaro, MD
- Phone Number: 4566 +49 89-1218
- Email: fusaro@dhm.mhn.de
-
Contact:
- Tarek Ibrahim, MD
- Phone Number: 4016 +49 89-1218
- Email: ibrahim@dhm.mhn.de
-
Principal Investigator:
- Massimiliano Fusaro, MD
-
Muenchen, Germany, 81675
- Recruiting
- I. Medizinische Klinik, Klinikum rechts der Isar
-
Contact:
- Ilka Ott, MD
- Phone Number: 4360 +49-89-4140
- Email: ott@dhm.mhn.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic ≥ 70% stenosis of the SFA (Rutherford stage 2-6)
- Written informed consent
Exclusion Criteria:
- Acute ischemia and/or acute thrombosis of the SFA
- Untreated ipsilateral iliac artery stenosis >70%
- Previous stenting of the SFA
- Popliteal stenosis >70%
- Severe renal insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Stenting
Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
|
Nitinol stent
Other Names:
|
Experimental: Stenting after PEB
Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
|
Nitinol stent
Other Names:
Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
Other Names:
|
Experimental: Atherectomy
The third randomization arm is Atherectomy.
|
Atherectomy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage diameter stenosis
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All-cause mortality
Time Frame: 6 and 24 months
|
6 and 24 months
|
Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)
Time Frame: 6 months
|
6 months
|
Time to onset of any of MAPE.
Time Frame: 3-24 months
|
3-24 months
|
Binary restenosis rate
Time Frame: 6 months
|
6 months
|
Percentage diameter stenosis in duplex ultrasound
Time Frame: 6 and 24 months
|
6 and 24 months
|
Change from baseline in functional status and health related quality of life (Walking Impairment Questionaire)
Time Frame: 3 and 6 months
|
3 and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ilka Ott, MD, Klinikum rechts der Isar
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GE IDE No. B00101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Diseases
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
Clinical Trials on Stenting (Smart Stent)
-
Cordis CorporationCompletedArterial Occlusive DiseasesGermany
-
Instituto Ecuatoriano de Enfermedades DigestivasActive, not recruitingBiliary Tract DiseasesEcuador
-
Al-Azhar UniversityEnrolling by invitationIdiopathic Intracranial HypertensionEgypt
-
RenJi HospitalFirst People's Hospital of Hangzhou; Fudan University; Xuanwu Hospital, Beijing; First Affiliated Hospital of Zhejiang University and other collaboratorsRecruitingPeripheral Arterial DiseaseChina
-
University of Turin, ItalyNot yet recruitingAneurysm Abdominal | Arterial Aneurysm
-
Chinese University of Hong KongRecruitingPancreatic Fistula | PancreatectomyHong Kong
-
Can Tho Stroke International Services HospitalAcandis GmbHRecruitingIschemic Stroke | Stent Stenosis | Intracranial AtherosclerosisVietnam
-
Yonsei UniversityUnknownFemoropopliteal Artery DiseaseKorea, Republic of
-
InspireMDRecruitingCarotid Artery StenosisUnited States, Poland
-
Xuanwu Hospital, BeijingUnknown